BioNTech SE furnished a Form 6‑K announcing its third quarter 2025 financial results and corporate update. The company scheduled a conference call for 8:00 am EST on November 3, 2025 to discuss the results. A press release and presentation were provided as Exhibits 99.1 and 99.2 and are incorporated by reference. The materials are designated as furnished and not deemed filed under the Exchange Act unless specifically referenced in a future filing.
BioNTech SE announced the commencement of its public exchange offer for all outstanding shares of CureVac N.V., as disclosed in a press release furnished as Exhibit 99.1.
The report states this 6‑K is deemed filed and incorporated by reference into BioNTech’s registration statement on Form F-4 (File No. 333-289468) and its Forms S-8 (File Nos. 333-277105, 333-269740, 333-253263) from the filing date.
BioNTech SE filed an amended Form F-4 for an exchange offer to acquire all outstanding ordinary shares of CureVac N.V.. Each CureVac share will be exchanged for a number of BioNTech ADSs equal to $5.4641 divided by the 10‑day VWAP of BioNTech ADSs, subject to a collar that fixes the exchange ratio at 0.04318 if the VWAP is ≥ $126.55 or 0.06476 if ≤ $84.37.
The offer is scheduled to expire at 9:00 a.m. (New York City time) on December 3, 2025, unless extended. A minimum of 80% of CureVac’s issued and outstanding capital must be tendered (which may be reduced to 75% in certain circumstances). Shareholders representing approximately 57% of CureVac shares have entered tender and support agreements. Following acceptance, a subsequent offering period of at least 10 business days will be provided.
After the offer, a post‑offer reorganization is planned so that BioNTech becomes the sole owner of CureVac’s business. CureVac holders who do not tender will receive the same consideration in that process, though amounts received there may be subject to 15% Dutch dividend withholding tax in certain cases. Delivery of ADSs is expected about 10 business days after each required German capital increase becomes effective and could take up to three weeks or more.
BioNTech SE filed a Form 6‑K to inform investors that on October 1, 2025 it hosted its second AI Day together with its artificial intelligence company InstaDeep Ltd. This event is part of BioNTech’s “Innovation Series” and provided an overview of its AI strategy, its AI capabilities, and how AI is applied across BioNTech’s product pipeline and internal processes.
The related investor presentation, offering more detail on these AI initiatives, is furnished as Exhibit 99.1 to the report.
BioNTech SE filed a Form 6-K noting that it and Bristol Myers Squibb have presented interim data from a global randomized Phase 2 trial of pumitamig (BNT327/BMS986545) in extensive-stage small cell lung cancer. The investigational bispecific antibody targets PD-L1 and VEGF-A and is being evaluated in combination with chemotherapy. According to the attached press release description, the interim Phase 2 data show encouraging antitumor activity in this patient population.
BioNTech entered a materially significant collaboration with Bristol-Myers Squibb to develop and commercialize the investigational bispecific antibody BNT327. Under the amended and restated agreement, BMS will pay $1.5 billion upfront plus $2.0 billion in non-contingent anniversary payments through 2028, and BioNTech is eligible for up to $7.6 billion in additional milestones. The parties will equally share global profits and losses and will generally split development costs equally, with adjusted sharing when one party contributes proprietary assets to a combination trial. BioNTech will initially supply clinical material and lead manufacturing transfer to BMS, after which BMS will assume commercial supply while BioNTech retains the right to supply a percentage of commercial product. Co-exclusive IP licenses and joint governance structures for development and commercialization are established.
BioNTech SE (BNTX) Form 144 notice reports a proposed sale of 500,000 American Depositary Shares through Goldman Sachs & Co. LLC with an approximate aggregate market value of $56,230,000 and an approximate sale date of 09/05/2025. The ADS class shows 237,725,735 shares outstanding. The filing states the 500,000 ADS were originally acquired in a private placement on 01/05/2018 from BioNTech SE and paid in cash. The notice also lists multiple prior sales by AT Impf GmbH during the past three months, including transactions on 06/05/2025 (50,000 ADS), 07/10/2025 (40,000 ADS), and several July 2025 dates down to 4,500 and 500 ADS, each with reported gross proceeds. The filer certifies no undisclosed material adverse information.
BioNTech SE reported that a pivotal Phase 3 trial of its antibody-drug conjugate candidate trastuzumab pamirtecan (BNT323/DB-1303), developed with Duality Biologics, met its primary goal. The study, conducted by DualityBio in China, compares BNT323/DB-1303 with trastuzumab emtansine (T-DM1) in patients with HER2-positive unresectable or metastatic breast cancer who have already received trastuzumab and a taxane-based chemotherapy.
At a pre-specified interim analysis, the trial achieved its primary endpoint of progression free survival, meaning patients on BNT323/DB-1303 lived longer without their cancer worsening than those on the comparator. A detailed press release with more information on the results is referenced as an exhibit to this report.
BioNTech SE reports that the U.S. Food and Drug Administration has approved a supplemental Biologics License Application for its and Pfizer’s LP.8.1‑adapted monovalent COVID‑19 vaccine, COMIRNATY LP.8.1. The vaccine is now approved for adults aged 65 and older and for individuals aged 5 through 64 who have at least one underlying condition that puts them at high risk for severe COVID‑19. This expands use of the updated mRNA vaccine in key higher‑risk groups in the United States.
Form 144 filing for BioNTech SE (BNTX) shows a proposed sale of 1,774,837 American Depositary Shares representing ordinary shares, with an aggregate market value of $200,024,129.90. The sale is reported through Berenberg Capital Markets LLC on 08/15/2025 and the shares are listed on the Nasdaq Global Select. The filing discloses that the seller acquired the underlying ordinary shares via stock option exercises on 08/09/2024 (918,651 shares) and 11/21/2022 (856,186 shares). The filing reports no sales in the prior three months and includes the standard representation that the seller is not aware of undisclosed material adverse information.